Proteomics analysis reveals biomarkers for early detection of rituximab response in children with immune thrombocytopenia, suggesting new personalized therapy avenues.
Key Points
Main findings indicate candidate biomarkers for rituximab response in pediatric patients with immune thrombocytopenia.
Identified 78 differential proteins before treatment and 67 after treatment using a proteomics approach.
Validating KLK6 and FUBP1 shows an area under the curve of 0.98 with high sensitivity and specificity.
These insights may lead to personalized therapy approaches for improving treatment outcomes in ITP.